54.63 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||54.61 x 900|
|Ask||54.70 x 900|
|Day's Range||53.86 - 54.85|
|52 Week Range||47.79 - 74.44|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||75.88|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.92|
Orthofix Medical Inc. (OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the first commercial implants of patients with the M6-C™ artificial cervical disc. The Center for Disc Replacement at Texas Back Institute (TBI) in Dallas, Texas recently implanted four patients suffering from single level cervical disc degeneration with the newly approved M6-C disc -- a next-generation artificial disc developed to replace an intervertebral disc damaged by cervical disc degeneration. Designed with an artificial viscoelastic nucleus and fiber annulus that mimics the anatomic structure of a natural disc, the M6-C device is the only artificial cervical disc available in the U.S. that enables compression or “shock absorption” at the implanted level.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for th...
The primary goal of the study was to assess the safety and efficacy of Orthofix's (OFX) M6-C artificial cervical disc in comparison to ACDF treatment.
Orthofix Medical Inc. (OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the full two-year outcomes from its U.S. Investigational Device Exemption (IDE) study of the M6-C™ artificial cervical disc. Dr. Jack Zigler, orthopedic spine surgeon at Texas Back Institute and an investigator in the study, presented the study results during the International Society for the Advancement of Spine Surgery (ISASS) annual meeting in Anaheim, California. The data demonstrates that patients treated with the M6-C artificial cervical disc had significant improvements in neck and arm pain, function and quality of life scores.
It might be of some concern to shareholders to see the Orthofix Medical Inc. (NASDAQ:OFIX) share price down 11% in the last month. But that doesn't change the fact thatRead More...
FDA approval of a key addition to the Orthofix (NASDAQ: OFIX) line of cervical spine products wasn't enough to offset investor concerns about a gross margin squeeze when the company reported fourth quarter and full year results at the end of February. Warning! GuruFocus has detected 4 Warning Signs with TSLA. Perhaps the beat down may have been worse if the company hadn't earlier announced approval of the M6-C artificial cervical disc for patients suffering from cervical disc degeneration.
Orthofix Medical Inc (NASDAQ: OFIX ) reported quarterly results Monday that were broadly in-line with expectations while guiding to higher spending and linear revenue growth. Investors can look past the ...
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Orthofix International NV (NASDAQ: OFIX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019 ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Orthofix Medical Inc. (NASDAQ:OFIX) is a stock with outstanding fundamentalRead More...
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orthofix Medical Inc. (OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced U.S. Food and Drug Administration (FDA) approval of the M6-C™ artificial cervical disc for patients suffering from cervical disc degeneration. The M6-C artificial cervical disc was developed by Spinal Kinetics, a company acquired by Orthofix in April 2018. “With the approval of the M6-C artificial cervical disc, Orthofix now has the industry’s most comprehensive portfolio of cervical spine products to best serve our surgeon customers and patients,” said Orthofix President and Chief Executive Officer, Brad Mason.
Orthofix Medical Inc. (OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it plans to release financial results for the fourth quarter and fiscal 2018 after market close on Monday, February 25, 2019. Brad Mason, Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company’s results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (844) 809-1992 in the U.S. and (612) 979-9886 outside the U.S., and referencing the conference ID 7446347.
Orthofix Medical Inc. (OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it has acquired the business of Options Medical, LLC, a medical device distributor based in Florida. Under the terms of the agreement, employees of Options Medical became employees of Orthofix effective February 1, 2019. “Options Medical started in North Central Florida as a small team of hard working individuals who wanted to provide the best in medical device solutions to physicians,” said Beth Stevenson, Distributor Principal and founder of Options Medical.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
Orthofix Medical Inc. today announced preliminary unaudited fourth quarter 2018 net sales of approximately $121 million. These preliminary results represent reported sales growth of 3.5% and constant currency sales growth of 4.3% over the fourth quarter 2017.
Orthofix Medical Inc. , a global medical device company focused on musculoskeletal products and therapies, today announced that President and Chief Executive Officer Brad Mason will present at the J.P.
Several planned developments, early benefits from new pharmacy contracts as well as increased volumes are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.
Brad Mason has been the CEO of Orthofix Medical Inc (NASDAQ:OFIX) since 2013. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After Read More...
Orthofix (OFIX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Orthofix (OFIX) delivered earnings and revenue surprises of 35.14% and 1.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
LEWISVILLE, Texas (AP) _ Orthofix Medical Inc. (OFIX) on Monday reported a third-quarter loss of $1.2 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Lewisville, Texas-based company said it had a loss of 7 cents. The medical device maker posted revenue of $111.7 million in the period.